Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease.
Furney SJ., Simmons A., Breen G., Pedroso I., Lunnon K., Proitsi P., Hodges A., Powell J., Wahlund LO., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Spenger C., Lathrop M., Shen L., Kim S., Saykin AJ., Weiner MW., Lovestone S., Alzheimer’s Disease Neuroimaging Initiative None., AddNeuroMed Consortium None.
Alzheimer's disease (AD) is a progressive neurodegenerative disorder with considerable evidence suggesting an initiation of disease in the entorhinal cortex and hippocampus and spreading thereafter to the rest of the brain. In this study, we combine genetics and imaging data obtained from the Alzheimer's Disease Neuroimaging Initiative and the AddNeuroMed study. To identify genetic susceptibility loci for AD, we conducted a genome-wide study of atrophy in regions associated with neurodegeneration in this condition. We identified one single-nucleotide polymorphism (SNP) with a disease-specific effect associated with entorhinal cortical volume in an intron of the ZNF292 gene (rs1925690; P-value=2.6 × 10(-8); corrected P-value for equivalent number of independent quantitative traits=7.7 × 10(-8)) and an intergenic SNP, flanking the ARPP-21 gene, with an overall effect on entorhinal cortical thickness (rs11129640; P-value=5.6 × 10(-8); corrected P-value=1.7 × 10(-7)). Gene-wide scoring also highlighted PICALM as the most significant gene associated with entorhinal cortical thickness (P-value=6.7 × 10(-6)).